



American Society of Clinical Oncology

Due to the nature of a print publication, some changes were made to abstract information after the 2008 Annual Meeting Proceedings I was published. The following abstracts were withdrawn post-publication and are listed here:

1044

Biotinylated trastuzumab immunoreactivity and p95 status identify HER2-amplified advanced breast cancer patients achieving reduced benefit from trastuzumab-based therapy.
First author: F. Montemurro

3505

A multi-center phase II study of volociximab in patients with relapsed metastatic melanoma.
First author: G. Linette

5545

Low HER3 expression may indicate a novel patient subgroup with poor prognosis but improved overall survival when treated with pertuzumab and gemcitabine for platinum resistant epithelial ovarian cancer (EOC).
First author: L. Amler

Publish-only Abstracts

11500

PIK3CA activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
First author: C. Liedtke

14530

Sunitinib malate as consolidation therapy in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): a phase II study.
First author: R. Gervais

14638

Changes in serological biomarkers of cell death during therapy in small cell lung cancer (SCLC) patients receiving platinum-based chemotherapy.
First author: A. P. Greystoke

22009

HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197.
First author: F. L. Baehner

22022

HER2 assessment in a large Kaiser Permanente case-control study: Comparison of fluorescence in situ hybridization (FISH) and quantitative reverse transcription polymerase chain reaction (RT-PCR) performed by central laboratories.
First author: L. A. Habel

22117

The ret oncogene—A novel target for therapy in some breast cancers?
First author: G. Thomas